Trials / Completed
CompletedNCT00765674
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,191 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aliskiren | 150 and 300 mg tablets |
| DRUG | Amlodipine | 5 and 10 mg capsules |
| DRUG | Hydrochlorothiazide (HCTZ) | 12.5 and 25 mg capsules |
| DRUG | Placebo | tablet |
| DRUG | Placebo | capsules |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2008-10-03
- Last updated
- 2011-05-09
- Results posted
- 2011-05-09
Locations
12 sites across 12 countries: United States, Australia, Canada, Denmark, Germany, Israel, Italy, Latvia, Lithuania, Romania, Sweden, Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00765674. Inclusion in this directory is not an endorsement.